|Clinical Trial Title||A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer|
|Trial Status||Closed to Enrollment|
|Location||Doctors & Locations|
|Trial Type||Cancer - Adult Oncology|
|Specific Condition||Endometrial cancer|
|Description||This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.
|IRB Number||Central IRB|
|Principal Investigator||Colleen McCormick, MD|
|Contact Name||Oncology Clinical Research|